<DOC>
	<DOCNO>NCT02546700</DOCNO>
	<brief_summary>Phase II , randomize , double-blind , placebo-controlled , parallel-group clinical trial lebrikizumab participant COPD history exacerbation treat inhaled corticosteroid ( ICS ) least one long-acting bronchodilator inhaler medication . This study conduct assess safety , efficacy , patient-reported outcome ( PRO ) measure .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Lebrikizumab Participants With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Documented history COPD great equal ( &gt; /= ) 12 month prior Visit 1 Postbronchodilator FEV1/FVC le ( &lt; ) 0.70 Visit 1 2 Post bronchodilator FEV1 &lt; 80 % predict Visit 1 2 Documented history one acute COPD exacerbation require treatment systemic corticosteroid and/or antibiotic hospitalization within 12 month prior Visit 1 Current tobacco smoker former smoker ( stop smoke least 6 month prior Visit 1 ) history smoke &gt; /=10 packyears ( 20 cigarettes/day 10 year ) On inhaled corticosteroid ( ICS ) therapy &gt; /=6 month prior Visit 1 On eligible bronchodilator medication &gt; /=6 month prior Visit 1 Chest Xray compute tomography ( CT ) scan within 6 month prior Visit 1 chest Xray prior Visit 2 confirms absence clinically significant lung disease besides COPD Demonstrated adherence background COPD inhaler medication screen period For female participant childbearing age , use single combine contraceptive method duration study History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity lebrikizumab injection History clinically significant pulmonary disease COPD Diagnosis alpha1antitrypsin deficiency Lung volume reduction surgery procedure within 12 month prior Visit 1 Supplemental oxygen requirement &gt; 2 liters/minute ( L/min ) rest exertion Current diagnosis asthma Participants participate , schedule , intensive COPD rehabilitation program Maintenance oral corticosteroid therapy Treatment systemic corticosteroid within 4 week prior Visit 1 screen period Unstable ischemic heart disease relevant cardiovascular disorder Use immunomodulatory immunosuppressive therapy include monoclonal antibody ( include antiinterleukin13 ( IL ) antiIL4/IL13 therapy ) Body weight &lt; 40 kg Any infection result hospital admission &gt; /= 24 hour and/or treatment oral , intravenous ( IV ) , intramuscular ( IM ) antibiotic within 4 week prior Visit 1 screen Upper low respiratory tract infection within 4 week prior Visit 1 screen Active parasitic Listeria monocytogenes infection within 6 month prior Visit 1 screen Received live attenuate vaccine within 4 week prior Visit 1 screen Active tuberculosis require treatment within 12 month prior Visit 1 Human immunodeficiency virus ( HIV ) know immunodeficiency Hepatitis know liver cirrhosis Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ATL ) , total bilirubin elevation &gt; /=2.0 x upper limit normal ( ULN ) screen Clinically significant abnormality screen electrocardiogram ( ECG ) laboratory test History alcohol drug abuse Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>